Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie is conducting a Phase 3 clinical study ...

Key takeaways: 42.4% of adolescents with severe alopecia areata who received baricitinib had 80% or more scalp hair coverage after 36 weeks. An expert said it is the largest trial to date studying ...

Thermo Fisher Scientific Inc. TMO focuses on expanding through the acquisition of technologies and businesses that augment its existing products and services. The company continues to enhance its ...

Alopecia areata significantly impacts mental health and employment, especially in non-White individuals, with higher risks of anxiety and depression. Asian and urban populations show the highest ...

Late-breaking results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) found adolescent patients (ages 12 to under 18) with severe alopecia areata (AA) treated with once-daily ...

Adolescents with alopecia areata achieve hair regrowth with 80% or more of scalp coverage while taking the Janus kinase inhibitor baricitinib, a phase 3 study finds.

Ritlecitinib demonstrates long-term improvements in regrowth of scalp hair, eyebrows, and eyelashes at 24 months in adults and adolescents with alopecia areata (AA) and ≥ 25% scalp hair loss. Of ...

HealthDay News — For adolescents with severe alopecia areata (AA), baricitinib is efficacious for hair regrowth, according to a study presented at the annual meeting of the American Academy of ...

WALTHAM, Mass., February 05, 2025--Thermo Fisher Scientific Inc. announced the launch of the international CorEvitas Adolescent Alopecia Areata (AA) Registry.

Patients share what they wish they had known before getting a diagnosis of alopecia areata, an autoimmune disease that causes hair loss.

"Early onset alopecia areata can be more severe, leading to extensive hair loss that frequently does not improve with topicals or corticosteroids often prescribed as first-line therapy," said ...

Late-breaking results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) found adolescent patients (ages 12 to under 18) with severe alopecia areata (AA) treated with once-daily, oral ...